CCRM
Mike Wang is an experienced professional in the field of quality control and scientific research, currently serving as a Quality Control Associate II at CCRM since September 2019. Previously, Mike worked as a Scientist at SGS from August 2015 to September 2019 and held the position of Senior Research Associate at the University of Waterloo from September 1998 to June 2013. Mike holds a PhD in Plant Molecular Biology from Penn State University, earned between 1989 and 1994.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.